Agent-based modelling reveals strategies to reduce the fitness and metastatic potential of circulating tumour cell clusters.
agent‐based model
anoikis
cancer
circulating tumour cell clusters
metastasis
Journal
Evolutionary applications
ISSN: 1752-4571
Titre abrégé: Evol Appl
Pays: England
ID NLM: 101461828
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
03
11
2019
revised:
14
02
2020
accepted:
20
02
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
Metastasis-the ability of cancer cells to disperse throughout the body and establish new tumours at distant locations-is responsible for most cancer-related deaths. Although both single and clusters of circulating tumour cells (CTCs) have been isolated from cancer patients, CTC clusters are generally associated with higher metastatic potential and worse prognosis. From an evolutionary perspective, being part of a cluster can provide cells with several benefits both in terms of survival (e.g. protection) and reproduction (group dispersal). Thus, strategies aimed at inducing cluster dissociation could decrease the metastatic potential of CTCs. However, finding agents or conditions that induce the dissociation of CTC clusters is hampered by the fact that their detection, isolation and propagation remain challenging. Here, we used a mechanistic agent-based model to (a) investigate the response of CTC clusters of various sizes and densities to different challenges-in terms of cell survival and cluster stability, and (b) make predictions as to the combination of factors and parameter values that could decrease the fitness and metastatic potential of CTC clusters. Our model shows that the resilience and stability of CTC clusters are dependent on both their size and density. Also, CTC clusters of distinct sizes and densities respond differently to changes in resource availability, with high-density clusters being least affected. In terms of responses to microenvironmental threats (such as drugs), increasing their intensity is, generally, least effective on high-density clusters. Lastly, we found that combining various levels of resource availability and threat intensity can be more effective at decreasing the survival of CTC clusters than each factor alone. We suggest that the complex effects that cluster density and size showed on both the resilience and stability of the CTC clusters are likely to have significant consequences for their metastatic potential and responses to therapies.
Identifiants
pubmed: 32821275
doi: 10.1111/eva.12943
pii: EVA12943
pmc: PMC7428819
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1635-1650Subventions
Organisme : NCI NIH HHS
ID : U54 CA217376
Pays : United States
Informations de copyright
© 2020 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd.
Références
Cancer Res. 2017 Nov 15;77(22):6442-6452
pubmed: 28923860
Cancer Res. 1976 Mar;36(3):889-94
pubmed: 1253177
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
Med Oncol. 2017 Jan;34(1):12
pubmed: 28012133
Mol Oncol. 2016 Mar;10(3):374-94
pubmed: 26897752
Front Oncol. 2019 Aug 29;9:842
pubmed: 31555595
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Cancer Res. 2018 Sep 1;78(17):5155-5163
pubmed: 29967263
Nat Rev Cancer. 2018 Nov;18(11):707-719
pubmed: 30327499
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Sci Rep. 2019 May 28;9(1):7933
pubmed: 31138856
Cancer Res. 2015 Nov 1;75(21):4474-82
pubmed: 26527605
Oncogene. 2016 Mar 10;35(10):1216-24
pubmed: 26050619
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1595-600
pubmed: 22307617
Lung. 2015 Jun;193(3):451-2
pubmed: 25821178
Cancer Res. 2010 Oct 15;70(20):7755-63
pubmed: 20924100
Cytometry A. 2017 Mar;91(3):250-253
pubmed: 28009470
Cancer Res. 2019 Nov 1;79(21):5527-5535
pubmed: 31481500
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
Acta Pharmacol Sin. 2018 Aug;39(8):1326-1337
pubmed: 29417941
Cancer Res. 2018 Feb 15;78(4):845-852
pubmed: 29437766
Cancer Res. 2016 Aug 15;76(16):4910
pubmed: 27528582
Mol Oncol. 2017 Jul;11(7):770-780
pubmed: 28544498
Trends Cancer. 2015 Sep;1(1):44-52
pubmed: 28741562
Cancer Res. 2018 Apr 15;78(8):2127-2139
pubmed: 29382708
Biochim Biophys Acta. 2016 Dec;1866(2):221-231
pubmed: 27678419
J Thorac Oncol. 2012 Feb;7(2):306-15
pubmed: 22173704
Mol Oncol. 2016 Mar;10(3):443-9
pubmed: 26847851
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Proc Natl Acad Sci U S A. 2016 May 3;113(18):4947-52
pubmed: 27091969
Lung Cancer. 2019 Aug;134:147-150
pubmed: 31319973
Cancer Res. 2014 Mar 15;74(6):1661-9
pubmed: 24453004
Oncol Lett. 2016 Dec;12(6):4891-4895
pubmed: 28105198
Breast Cancer Res Treat. 2017 Jan;161(1):83-94
pubmed: 27771841
J Cell Physiol. 2019 Apr;234(4):4445-4453
pubmed: 30191978
Int J Oncol. 2016 Dec;49(6):2206-2216
pubmed: 27779656
Cancer Cell Int. 2017 Jan 5;17:6
pubmed: 28070168
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8215-20
pubmed: 18378900
J Clin Oncol. 2012 Feb 10;30(5):525-32
pubmed: 22253462
Sci Transl Med. 2012 Mar 7;4(124):124ra27
pubmed: 22323820
Front Oncol. 2018 Mar 12;8:63
pubmed: 29594043
J Cell Sci. 2019 Sep 9;132(17):
pubmed: 31409692
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E854-63
pubmed: 26831077
Breast Cancer Res Treat. 2015 Jun;151(3):491-500
pubmed: 25957595
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Sci Rep. 2017 May 26;7(1):2433
pubmed: 28550299
Cancer Res. 2016 Aug 15;76(16):4909
pubmed: 27528581
Oncotarget. 2017 Jan 10;8(2):3029-3041
pubmed: 27935872